VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
| Autor: | Kanako Hosono, Ko Hatanaka, Hideki Amano, Yoshiya Ito, Yoshio Matsui |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Immunology Review Pulmonary fibrosis SDF-1 03 medical and health sciences chemistry.chemical_compound Idiopathic pulmonary fibrosis 0302 clinical medicine Growth factor receptor Pathology medicine RB1-214 Immunology and Allergy CXCR4 biology VEGFR1-TK business.industry respiratory system medicine.disease respiratory tract diseases Vascular endothelial growth factor 030104 developmental biology VEGFR1+ cells chemistry Fibroblast growth factor receptor 030220 oncology & carcinogenesis cardiovascular system biology.protein Cancer research Nintedanib business Tyrosine kinase Platelet-derived growth factor receptor |
| Zdroj: | Inflammation and Regeneration, Vol 41, Iss 1, Pp 1-8 (2021) Inflammation and Regeneration |
| ISSN: | 1880-8190 |
| DOI: | 10.1186/s41232-021-00166-7 |
| Popis: | Vascular endothelial growth factor (VEGF) is not only an important factor for angiogenesis but also lung development and homeostasis. VEGF-A binds three tyrosine kinase (TK) receptors VEGFR1–3. Idiopathic pulmonary fibrosis (IPF) is one of the poor prognoses of lung diseases. The relationship of VEGF and IPF remains to be clarified. Treatment with nintedanib used for the treatment of IPF reduced fibroblast proliferation, inhibited TK receptors, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and VEGFR. Because the effect of that treatment is still not satisfactory, the emergence of new therapeutic agents is needed. This review describes the enhancement of pulmonary fibrosis by VEGFR1-TK signal and suggests that the blocking of the VEGFR1-TK signal may be useful for the treatment of pulmonary fibrosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink